Salve, Pancho! Dove' andato? (Hi, Pancho! Wher ya been?)
Ya, you're probably in Compobasso...and I'm jealous! OK, let's talk about CNTO...the 27 1/2 support held, thank God, and things looking better. Hopefully, most of the negative stuff (and downgrades) is OUT, including the 'impatient' investors/traders. The stock may retreat to 30, but I expect it to see test 35 resistance first, bounce around ... and then test 39. But we do need some good news...are you listening, CEO Holveck???
In regards to IPIC, their CerAxon (citicoline) hasn't helped their stock and neither has their diet drug...take a look at their chart. Still going south. Quite frankly, the FDA may be a little tough on their drug application for ischemic stroke. Let's hope CNTO shows better results.
"Results of clinical trials with CerAxon in the U.S. have demonstrated that patients with moderate to severe strokes treated with this drug experienced significantly improved neurological and cognitive function relative to patients receiving placebo," the company (IPIC) said in a prepared statement.
Incidently, we now have a nice group of doctor investors (Thiers, Pagani, and Black) who I think should be congratulated for posting their views. In the biotech arena it is specially important to obtain a medical perspective as well the financial and TA(?)/fundamental viewpoints.
Thanks for your input....long CNTO!
FNS
|
